- CEO
- Lu Wei Zhang
- Full Time Employees
- 981
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Changge China
- IPO Date
- Nov 16, 2022
- Business
- Newland Pharmaceutical Co., Ltd. is a China-based pharmaceutical manufacturing company engaged in the research, development, production, and commercial distribution of chiral pharmaceutical intermediates, active pharmaceutical ingredients (APIs), finished dosage formulations, and contract development and manufacturing organization (CDMO) services. Founded in 2005 and headquartered in Changge, Henan Province, China, the company operates across the healthcare and specialty chemical sectors. The company's core operations are structured into three main segments: Pharmaceutical Intermediates, Active Pharmaceutical Ingredients, and Formulations and CDMO Services. Its Pharmaceutical Intermediates segment specializes in chiral chemical compounds and key antibiotic building blocks, comprising D-p-hydroxyphenylglycine (D-acid), D-p-hydroxyphenylglycine methyl ester, D-p-hydroxyphenylglycine potassium Dane salt, and glyoxylic acid utilized primarily in the synthesis of semi-synthetic penicillins and cephalosporins such as amoxicillin, cefprozil, cefadroxil, and cefoperazone; alongside p-toluenesulfonic acid and related derivatives utilized in the production of doxycycline hydrochloride. Its Active Pharmaceutical Ingredients segment manufactures pharmaceutical-grade bulk substances across diverse therapeutic categories, including local anesthetics such as lidocaine hydrochloride, lidocaine base, and ropivacaine hydrochloride; anti-infectives and respiratory antibiotics such as moxifloxacin hydrochloride and gatifloxacin; proton pump inhibitors and gastrointestinal treatments such as esomeprazole sodium, esomeprazole magnesium, and omeprazole; antigout and cardiovascular therapies such as febuxostat and clopidogrel bisulfate; antidiabetic agents including vildagliptin; urological treatments including tadalafil; and antihistamines and nasal decongestants including chlorpheniramine maleate and naphazoline hydrochloride. In addition, the company provides customized CDMO solutions encompassing process optimization, route verification, analytical method development, and commercial-scale toll manufacturing. The company distributes its products domestically across China and exports to international markets including Europe, the United States, India, Japan, and other Asia-Pacific regions, supported by European Certificates of Suitability (CEP), U.S. FDA Drug Master File (DMF) filings, and ISO-certified manufacturing infrastructure. In recent developments, the company changed its corporate name from Henan Newland Pharmaceutical Co., Ltd. to Newland Pharmaceutical Co., Ltd. to reflect its expanded nationwide and global business footprint. Under its vertically integrated strategy advancing from intermediates toward bulk APIs and finished dosages, the company completed and brought into operation its 120-ton annual capacity active pharmaceutical ingredient production facility and intelligent specialty API supply chain project in late 2025. Furthermore, the company expanded its commercialized API portfolio with the regulatory approval of etomidate API, received European CEP certification for moxifloxacin hydrochloride API to accelerate global market penetration, and progressed the development and clinical evaluation of its downstream finished drug pipeline, including oral solid dosage forms such as oseltamivir phosphate capsules and ruxolitinib phosphate tablets.